These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
259 related items for PubMed ID: 26433844
1. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Huen AO, Kim EJ. Dermatol Clin; 2015 Oct; 33(4):715-29. PubMed ID: 26433844 [Abstract] [Full Text] [Related]
2. [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma]. Rodriguez Suarez S, Pamies Andreu E, Muñiz Grijalvo O, Garcia Morillo JS. Med Clin (Barc); 2016 Feb 05; 146(3):117-20. PubMed ID: 26688184 [Abstract] [Full Text] [Related]
3. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, Kulikowski W, Prejzner W, Romejko-Jarosinska J, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Rogowski W, Grzanka A, Placek W, Lugowska-Umer H, Kowalczyk A, Nowicki R, Jurczak W. Am J Ther; 2016 Feb 05; 23(3):e749-56. PubMed ID: 24732904 [Abstract] [Full Text] [Related]
4. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas. Serri F, De Simone C, Venier A, Rusciani L, Marchetti F. Curr Probl Dermatol; 1990 Feb 05; 19():252-7. PubMed ID: 2404681 [No Abstract] [Full Text] [Related]
5. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. Spaccarelli N, Rook AH. Dermatol Clin; 2015 Oct 05; 33(4):731-45. PubMed ID: 26433845 [Abstract] [Full Text] [Related]
6. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients. Bouwhuis SA, Davis MD, el-Azhary RA, McEvoy MT, Gibson LE, Knudsen JM, Kist JM, Pittelkow MR. J Am Acad Dermatol; 2005 Jun 05; 52(6):991-6. PubMed ID: 15928617 [Abstract] [Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. J Am Acad Dermatol; 2014 Feb 05; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970 [Abstract] [Full Text] [Related]
8. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma. Nguyen CV, Bohjanen KA. Dermatol Clin; 2015 Oct 05; 33(4):683-96. PubMed ID: 26433841 [Abstract] [Full Text] [Related]
10. State of the art therapy of mycosis fungoides and Sézary syndrome. Kemme DJ, Bunn PA. Oncology (Williston Park); 1992 Feb 05; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501 [Abstract] [Full Text] [Related]
15. Bexarotene and systemic disease progression in CTCL? Dummer R, Hauschild A, Skalsky J, Burg G, Weichenthal M. J Am Acad Dermatol; 2006 Aug 05; 55(2):365-6; author reply 366. PubMed ID: 16844539 [No Abstract] [Full Text] [Related]
16. Treatment of mycosis fungoides with oral bexarotene combined with PUVA. Stern DK, Lebwohl M. J Drugs Dermatol; 2002 Sep 05; 1(2):134-6. PubMed ID: 12847736 [Abstract] [Full Text] [Related]
17. Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298. Tousignant J, Raymond GP, Light MJ. J Am Acad Dermatol; 1987 Jan 05; 16(1 Pt 2):167-71. PubMed ID: 3493269 [Abstract] [Full Text] [Related]
19. Sézary syndrome in an 11-year-old girl. Meister L, Duarte AM, Davis J, Perez JL, Schachner LA. J Am Acad Dermatol; 1993 Jan 05; 28(1):93-5. PubMed ID: 8425978 [Abstract] [Full Text] [Related]
20. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Kempf W, Kettelhack N, Duvic M, Burg G. Hematol Oncol Clin North Am; 2003 Dec 05; 17(6):1405-19. PubMed ID: 14710892 [Abstract] [Full Text] [Related] Page: [Next] [New Search]